Physician profile
David M Culpepper
NPI 1235190018
$817.15
in general payments reported to CMS, 2019-2025
21 companies · $36.52 in 2025
The $36.52 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2024: $108 · 2025: $36.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $144.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $107.56 | 2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $104.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $81.54 | 2019 | |
| Amgen INC. | $67.63 | 2019 | |
| Astellas Pharma US INC | $63.18 | 2019 | |
| Pfizer INC. | $61.76 | 2019 | |
| Novo Nordisk INC | $51.32 | 2019 | |
| Glaxosmithkline, LLC. | $45.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.05 | 2019 | |
| Harmony Biosciences LLC | $36.52 | 2025 | |
| Merck Sharp & Dohme LLC | $31.26 | 2019 | |
| Antares Pharma, INC. | $15.38 | 2019 | |
| Amarin Pharma, INC. | $14.42 | 2019 | |
| Genentech USA, INC. | $14.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.20 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $12.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.83 | 2019 | |
| Mylan Specialty L.P. | $11.67 | 2019 | |
| Lilly USA, LLC | $11.65 | 2019 | |
| Hikma Pharmaceuticals USA | $11.55 | 2019 | |
| Allergan, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Culpepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.